I-Mab (IMAB)
NASDAQ: IMAB · Real-Time Price · USD
2.570
+0.550 (27.23%)
At close: Jun 27, 2025, 4:00 PM
2.610
+0.040 (1.56%)
After-hours: Jun 27, 2025, 7:57 PM EDT
I-Mab Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
209.87M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
IMAB News
- 2 days ago - I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 - GlobeNewsWire
- 5 weeks ago - I-Mab to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 4 months ago - I-Mab Announces Accelerated Givastomig Phase 1b Study Progress - GlobeNewsWire
- 4 months ago - I-Mab to Participate in Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 5 months ago - I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 6 months ago - I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member - PRNewsWire
- 6 months ago - I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program - PRNewsWire